Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials
Open Access
- 25 April 2013
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 13 (1) , 26
Abstract
Indacaterol is a novel, once-daily (od), inhaled, long-acting ß2-agonist bronchodilator for maintenance treatment of airflow limitation in patients with COPD. The aim of this study was to evaluate the efficacy of indacaterol on dyspnea, using available randomized placebo-controlled trials. A systematic search was made of MEDLINE, EMBASE, the Cochrane trials databases, and a manual search of journals. Randomized placebo-controlled trials of 12 weeks or more comparing indacaterol with placebo were reviewed, and eligible studies were included in a meta-analysis. The odds ratio (OR) for likelihood of achieving TDI score ≥ 1 after 12 weeks of treatment was used as an outcome measure to compare indacaterol to placebo. Six trials were included in the analysis. Relative to placebo, the overall ORs for response were: indacaterol 75 μg od 1.784 (95% CI 1.282 to 2.482); indacaterol 150 μg od 2.149 (95% CI 1.746 to 2.645); and indacaterol 300 μg od 2.458 (95% CI 2.010 to 3.006). Overall OR for response in TDI tended to increase with higher indacaterol doses. Patients receiving indacaterol had clinically significant improvements in symptoms of dyspnea compared to placebo. Incremental benefits in TDI were observed with increasing doses. Indacaterol may provide patients and physicians with a useful treatment option in symptomatic patients with dyspnea.Keywords
This publication has 31 references indexed in Scilit:
- Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspectsDrug Discovery Today, 2012
- Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approachesRespiratory Research, 2011
- Effect of Indacaterol on Dynamic Lung Hyperinflation and Breathlessness in Hyperinflated Patients with COPDCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2011
- Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropiumRespiratory Research, 2010
- Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasoneInternational Journal of Chronic Obstructive Pulmonary Disease, 2010
- Once-daily indacaterolversustwice-daily salmeterol for COPD: a placebo-controlled comparisonEuropean Respiratory Journal, 2010
- Efficacy of a new once-daily long-acting inhaled 2-agonist indacaterol versus twice-daily formoterol in COPDThorax, 2010
- Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: BronchodilatorsProceedings of the American Thoracic Society, 2007
- Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEuropean Respiratory Journal, 2004
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986